Citadel Upgrades Questcor To Edge Positive, Raises PT To $44

August 9, 2011 6:12 AM | 8 seconds read |
Citadel Securities has upgraded Questcor Pharmaceuticals QCOR from Neutral to Edge Positive and has raised the price target from $23 to $44.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: UpgradesPrice TargetAnalyst Ratingscitadel securitiesHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!